Emerging Immunotherapies in the Treatment of Non–small Cell Lung Cancer (NSCLC)
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference54 articles.
1. . Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.;Pirker;Lancet,2009
2. M, von PJ, Zatloukal P, et al.. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.;J Clin Oncol,2009
3. . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.;Sandler;N Engl J Med,2006
4. Bevacizumab as first-line treatment for advanced non-small cell lung cancer.;Socinski;Drugs Today (Barc),2008
5. . Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.;Jackman;Clin Cancer Res,2009
Cited by 60 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Discovery of a Potential Inhibitor Against Lung Cancer: Computational Approaches and Molecular Dynamics Study;PHYS CHEM RES;2024
2. Effectiveness of immune checkpoint inhibitor therapy on bone metastases in non-small-cell lung cancer;Frontiers in Immunology;2024-06-18
3. Patients with Advanced or Metastasised Non-Small-Cell Lung Cancer with Viscum album L. Therapy in Addition to PD-1/PD-L1 Blockade: A Real-World Data Study;Cancers;2024-04-22
4. Durable complete response to PET‐CT driven stereotactic radiation therapy plus pembrolizumab for pleomorphic Pancoast cancer: Case report and literature review;Clinical Case Reports;2024-04
5. The emerging nanomedicine-based technology for non-small cell lung cancer immunotherapy: how far are we from an effective treatment;Frontiers in Oncology;2023-04-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3